Unmet Needs in the Treatment of Lung Cancer

EP. 1: Introduction: Exploration of Nab-Paclitaxel in NSCLC

July 16th 2014

EP. 2: Nab-Paclitaxel in Non-Small Cell Lung Cancer

July 16th 2014

EP. 3: Maintenance Nab-Paclitaxel in Squamous NSCLC

July 16th 2014

EP. 4: Subgroup Analyses for Nab-Paclitaxel in NSCLC

July 16th 2014

EP. 5: Next-Generation EGFR Inhibitors in NSCLC

July 16th 2014

EP. 6: AZD9291 and Rociletinib in T790M-Mutant NSCLC

July 16th 2014

EP. 7: Afatinib Plus Cetuximab in Resistant NSCLC

July 16th 2014

EP. 8: Frontline ALK, EGFR Inhibition in NSCLC

July 16th 2014

EP. 9: Next-Generation ALK Inhibitors in NSCLC

July 16th 2014

EP. 10: Utilizing Next-Generation ALK Inhibitors in NSCLC

July 16th 2014

EP. 11: Efficacy of Next-Generation ALK Inhibitors

July 16th 2014

EP. 12: PD-1 Inhibition in Lung Cancer

July 16th 2014

EP. 13: Nivolumab in Non-Small Cell Lung Cancer

July 16th 2014

EP. 14: Multiple PD-1/PD-L1 Agents in Lung Cancer

July 16th 2014

EP. 15: PD-1/PD-L1 Inhibitors Across NSCLC Treatment Settings

July 16th 2014

EP. 16: Role of Maintenance Therapy in NSCLC

July 16th 2014

EP. 17: Maintenance Therapy Clinical Trials for NSCLC

July 16th 2014

EP. 18: PointBreak and AVAPERL Studies in NSCLC

July 16th 2014

EP. 19: Emerging Therapies in Non-Small Cell Lung Cancer

July 16th 2014

EP. 20: Novel Angiogenesis Inhibitors in NSCLC

July 16th 2014

NEXT PAGE
PREVIOUS PAGE